(MedPage Today) — Treatment with the investigational oral, allosteric, selective AKT inhibitor engasertib appeared to be safe in patients with hereditary hemorrhagic telangiectasia (HHT), and was associated with decreases in epistaxis frequency…
Source link : https://www.medpagetoday.com/hematologyoncology/hematology/118745
Author :
Publish date : 2025-11-26 22:00:00
Copyright for syndicated content belongs to the linked Source.
